Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...
Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...
Mounjaro and Zepbound have seen great success generating huge revenues for Lilly. Lilly has also filed regulatory applications in the United States and EU to seek approval for tirzepatide for ...
Zacks.com on MSN16d
Lilly's Zepbound Receives FDA Approval for Sleep ApneaFDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.
Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...
Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...
Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in ...
Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback